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AVM is characterized by high-flow AV connections that shunt blood directly from arteries to veins, displacing intervening capillaries with a nidus of enlarged and tortuous vessels. BAVM clinical characteristics include (1) AV shunting, the presence of direct connections between arteries and veins, displacing intervening capillaries; (2) abnormally high blood flow through the feeding artery, AV shunt, and draining vein; (3) the presence of a focal nidus consisting of enlarged, tangled vessels; (4) intracerebral hemorrhage and ischemia and increased endothelial permeability; and (5) neurological deficits, including seizures, headache, unsteadiness, and stroke. Therefore, mouse models relevant to translational BAVM research should exhibit these anatomic, functional, and symptomatic features of the human disease.
Two different approaches have led to progress in genetically engineered mouse models of BAVM (Table) . Bedsideto-bench-heritable risk alleles in human patients have been mutated in mouse counterparts; conversely, Bench-tobedside-genes identified in embryonic AV specification have also been mutated in mice to provide new insight into the human disease. Here, we provide an overview of mouse models of BAVM developed by both approaches (Table; Table  I in the online-only Data Supplement).
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Bedside-to-Bench: Human Mutations Inspire Mouse Models of Hereditary Hemorrhagic
Telangiectasia-Mediated AVM Although most BAVMs are sporadic with no known genetic lesions, about 5% are associated with autosomal-dominant disorders (Table II in the online-only Data Supplement).
Hereditary hemorrhagic telangiectasia (HHT) is the most prevalent of these and is characterized by AVMs in multiple organs, including the brain. 33 HHT is mainly caused by mutations in Endoglin (ENG) (HHT1), encoding a transforming growth factor-β-binding protein, 33 and activin receptor-like kinase 1 (ACVRL1) (ALK1) (HHT2), encoding a cell-surface receptor for transforming growth factor-β ligands. 34 Both genes are expressed primarily by endothelial cells (ECs), but how deficiencies in either ENG or ALK1 lead to AVM pathology remains unclear. In addition, mutations to MADH4, which encodes for Smad4, an effector of transforming growth factor-β signaling, cause a combined juvenile polyposis syndrome and HHT. 35 HHT can also result from mutations in BMP9 36 and 2 unidentified genes on chromosome 5 (HHT3) 37 and on chromosome 7 (HHT4). 38 Furthermore, PTPN14, which encodes for a nonreceptor tyrosine phosphatase, shows genetic association with pulmonary AVMs in HHT. 39 These studies of familial HHT have revealed that multiple, heritable genetic lesions can lead to HHT-related AVMs.
Mutations in RASA1 and PTEN have been linked to AVM in humans. RASA1, which encodes for p120 Ras GTPaseactivating protein (a negative regulator of Ras/MAPK pathway), is mutated in capillary malformation-AVM. 40 Capillary malformation-AVM is an autosomal-dominant disorder that is characterized by cutaneous capillary malformations and AVMs, including BAVMs. 40 [10] [11] [12] [13] however, features of BAVM, including AV shunts, niduses of dilated vessels, and rounded, misaligned EC nuclei, occur in 30% of Eng +/− mice aged 25 to 40 weeks, similar to BAVM incidence in HHT1 patients. 12 Thus, loss of 1 allele of Eng or Alk1 is sufficient to induce BAVM in adult mice, but with incomplete penetrance.
The incomplete penetrance and focal BAVM development in Eng +/− and Alk1 +/− mice led to the hypothesis that these genetic perturbations require a second hit-a corroborating process or genetic lesion-in AVM formation. Data from human BAVM patients support the second hit hypothesis: (1) BAVM typically presents in adolescence or adulthood, even though patients harbor germline mutations 44 ; (2) a high level of angiogenic signaling near human AVM suggests that AVM may be triggered by angiogenesis 45 ; (3) somatic loss of heterozygosity has been observed in RASA1-mediated AVMs. 46 The finding that a genetic perturbation leads to BAVM in immature/ remodeling but not mature/quiescent mouse brains provides the first experimental evidence that angiogenic remodeling may be a permissive factor for AVM formation. 26, 28 Both classes of second hit candidates have been explored, resulting in more robust and tractable models of BAVM formation.
Local delivery of vascular endothelial growth factor (VEGF) results in local vascular dysplasia in Eng +/− or Alk1 +/− mice. Recombinant human VEGF injection into Eng +/− brains leads to microvascular abnormalities, including enlarged, tortuous, and clustered vessels, with 89% penetrance and 2-to 4-week latency.
14 Similarly, focal adenoviral VEGF delivery into the cerebral cortex of Eng +/− and Alk1 +/− adult mice results in abnormally enlarged capillaries and increased capillary density, with 6-week latency. 15 Notably, vascular defects are more profound in Eng +/− mice than in the Alk1 +/− mice. 15 Together, these studies support the possibility that VEGF-induced angiogenic stimulus can be a second hit for vascular dysplasia in Eng +/− and Alk1 +/− mice. The hypothesis that a somatic loss of heterozygosity increases AVM formation has been experimentally tested using genetic tools for tissue-specific, temporal gene deletion. Deletion of both alleles of Alk1 from embryos in a subset of Alk1 expressing cells results in late gestational or postnatal lethality with AVMs in the brain (Figure 2A) , 17, 18, 20 lung, and intestine. 16, 17 However, tamoxifen-dependent deletion of Alk1 from adult mice using R26-CreER T2 results in lung and intestinal AVMs, but is insufficient to induce BAVMs. 17 Together, these studies suggest that deletion of both Alk1 alleles is sufficient to induce BAVM during development, but not during adulthood.
Combination of local angiogenic stimulus and Alk1 or Eng deletion promotes BAVM formation in adult mice (refer to  Table) . Deletion of Alk1 or Eng, coupled with VEGF administration, results in signs of AVM, including enlarged and dysplastic vessels ( Figure 2B and 2C), [18] [19] [20] [21] AV shunting, 18, 20 irregular vessel aggregates, 18, 20 and microhemorrhage. 20, 23 These studies show that the loss of either Alk1 or Eng alleles, in conjunction with angiogenic stimulation, may lead to AVM formation. Endothelial deletion of Alk1 or Eng, in combination with angiogenic stimulus, results in features of nonbrain AVM in mice. Endothelial Alk1 deletion in adult mice leads to gastrointestinal AVM and hemorrhage 6 to 14 days after induction of gene deletion. 23, 24 Deletion of Eng from postnatal endothelium leads to AV shunting and increased EC proliferation in the developing retina. 22 However, angiogenic matrigel implantation or wounding is required to induce vascular defects in endothelial Eng-deficient skin. 22 
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Endothelial cell deletion during embryonic development
Ad-Cre+Alk1
+AAV-VEGF Local deletion in adults+angiogenic stimulus
By 8wk post AAV/Cre
+AAV-VEGF
Local deletion in adults/ germline null+ angiogenic stimulus By 8wk post AAV/Cre
Ad-Cre+Eng fx/fx
+AAV-VEGF Local deletion in adults+angiogenic stimulus
Endothelial cell deletion at birth Enlarged, tortuous vessels assembling into focal tangles are observed, as well as direct AV shunting. These studies raise the possibility that the loss of Eng or Alk1 from SMCs lead to AVM. However, these data remain controversial-SM22α-Cre-mediated recombination has been observed in some brain ECs, 25 potentially confounding the conclusion that gene deletion is confined to the SMC compartment. Whether perivascular HHT mutations drive AVM formation remains questionable: (1) Alk1 or Eng deficiency in adult ECs, but not SMCs, induces AVM in a skin wound model 24 ; (2) 
R26-CreER
deletion of
Alk1 from ECs, but not pericytes, along with focal delivery of VEGF leads to BAVM formation in adult mice. 23 Together, these studies suggest that endothelial, but not perivascular, Alk1 or Eng deficiency can result in AVM in combination with VEGF stimulation. However, altered perivascular cell coverage is associated with BAVM in mice. After VEGFinduced angiogenesis in Alk1-deficient brains, fewer pericytes, decreased PDGFR-β (platelet-derived growth factor receptor-beta) expression, and fewer vessels expressing α-smooth muscle actin are observed, suggesting reduced smooth muscle coverage. 23 The perivascular defects observed in animal models are similar to human AVM; however, the contribution of these defects to AVM progression remains unclear. Endothelial cell deletion in adults
Tie2-tTA; TRENotch1*
Constitutive activation in endothelial cells at 21 d
Tie2-tTA; TRENotch4* Constitutive activation in endothelial cells at 21 d
Tie2-tTA; TRENotch1* Constitutive activation in endothelial cells at birth
Tie2-tTA; TRENotch4* Constitutive activation in endothelial cells at birth 
Bench-to-Bedside: Mutations in the Notch Pathway Lead to Hallmarks of AVM in Mice
Investigations into the functions of genes regulating AV specification ( Figure 3A ) 29 have led to potential roles in AVM formation. Perturbations to signaling pathways that disrupt normal AV specification often lead to vascular abnormalities that resemble AV shunting in mice (Table III in the onlineonly Data Supplement). Differential AV expression patterns of Notch receptors persist in adult endothelium, suggesting that they are important in maintaining AV specification in adult. Carlson et al 26 first showed that the upregulation of Notch signaling in postnatal endothelium elicits AVM formation. Endothelial expression of a constitutively active Notch4 allele (Notch4*) in adult mice results in features of AVM in liver, skin, and uterus, but not in brain. Arterial marker expression is increased, suggesting arterialization of vessels in Notch4* adult mice. This seminal study opens the possibility that Notch, crucial in AV specification, may be important in AVM pathogenesis.
Endothelial expression of Notch4* in immature mice leads to hallmarks of BAVM. 28 Vascular lesions were completely penetrant when Notch4* was turned on from birth, causing lethality by P36 lesions exhibited the hallmarks of human BAVM, including enlarged, tortuous vessels, AV shunting, increased flow in the feeding carotid arteries, nidus formation, hemorrhage, and ataxia ( Figure 4A ). [27] [28] [29] Endothelial Notch4* increases arterial marker expression (Efnb2, Connexin40, Jagged1, Dll4) and decreases venous marker expression (Ephb4; Figure 3B and 3C), suggesting arterialization of the brain endothelium by Notch4*. 28, 29 Thus, unlike in adult brains, Notch4* is able to induce AVMs in immature brains, suggesting that immature brain vasculature is susceptible to Notch4*-induced AVM formation. Endothelial expression of constitutive Notch1 (Notch1*) in immature brains also leads to features of BAVM, indicating that increased activity of either Notch receptor is sufficient to cause BAVM. 27 In vivo time-lapse imaging of BAVM formation in Notch4* mice shows that AV shunts arise from microvessels with capillary-like diameter and blood flow profiles, without a significant increase in EC proliferation ( Figure 4B ). 27 Clinical observations suggest that increased flow through lowresistance AV shunts encourages their growth, whereas stealing blood flow from adjacent higher resistance vessels. 47 In this model, Notch4* permits steal and perpetuates a positive feedback loop, leading to selective growth of higher velocity at the expense of lower velocity AV connections. 27 Thus, Notch4* (and presumably Notch1*) promotes the initiation and progression of BAVM in mice ( Figure 4A ).
Conversely, blocking Notch signaling, via deletion of Rbpj, in postnatal endothelium also leads to features of BAVM in mice. 30 Endothelial deletion of Rbpj at birth results in tortuous vessels, AV shunting, vessel aggregates, hemorrhage, and signs of neurological deficits by P14 in the brain. AV shunts show decreased Efnb2 and increased Ephb4 expression, suggesting acquisition of venous identity. Data from the gain-and loss-of-function Notch models are consistent with the model that tight regulation of Notch signaling is essential to prevent BAVM in mice.
Crosstalk Between HHT and Notch Signaling Pathways
Gene expression changes in HHT mutant mice suggest a link between HHT and Notch signaling pathways in AVM formation. Loss of Alk1 function results in abnormal arteriovenous marker expression, both in embryonic and postnatal mice. 18, 31, 42 Alk1 signaling also synergizes with activated Notch in the endothelium to induce expression of Notch target genes. 48 These data suggest that Alk1 may affect the expression of Notch downstream genes.
Alk1/Notch crosstalk also functions in BAVM development. Deficiency of the extracellular bone morphogenetic protein (BMP) antagonist matrix Gla protein (MGP) leads to BAVM formation. 32 Alk1 is a receptor for BMPs, and thus an increase in available BMP results in increased Alk1 signaling. Mgp −/− mice develop features of BAVM by 4 weeks of age, with enlarged cerebrovascular vessels, AV shunting, and hemorrhage ( Figure 5 ). 32 Analysis of AV marker expression shows increased Efnb2 and decreased Ephb4 expression in Mgp −/− brains. Notch ligands Jagged 1 and 2 are upregulated in Mgp −/− brains and Mgp −/− BAVMs, and heterozygous deletion of Jagged 1 and 2 in Mgp −/− mice suppresses BAVM formation. These findings extend to cultured brain ECs, where BMP9 is sufficient to activate Notch signaling and induce arterial marker expression. 32 Together, these data suggest cooperation of Alk1 and Notch pathways in BAVM pathogenesis.
Attempts in Therapeutic Treatment of AVMs
Mechanisms that underlie BAVM pathogenesis remain unclear, limiting the rational design of specific molecular interventions. To date, there are no specific or approved medical therapies to treat AVMs or to prevent AVM hemorrhage. Current treatment strategies include medical management 49 and invasive procedures, such as surgical resection, stereotactic radiosurgery, and endovascular embolization. 50, 51 Treatment strategies aimed at inhibiting angiogenesis and maintaining vascular integrity have led to novel therapeutic approaches for the treatment of vascular malformations, including BAVMs (Table IV and text in the online-only Data Supplement). Further therapeutic development depends on an improved understanding of mechanisms underlying AVM pathogenesis, such as those uncovered using mouse models of BAVMs.
Reversal of AVM by Normalization of the Causal Notch Lesion in Mice
Correction of a molecular lesion allows the regression of existing BAVMs and leads to the restoration of AV specification in an animal model. In the Notch4* model, symptoms of AVM are eliminated on suppression of the Notch4* transgene, 28 along with rapid regression of the AV shunts, restoration of blood flow to distal arteries, and perfusion of the brain parenchyma ( Figure 4C) . 29 In addition, normal AV specification is restored in concert with the regression of existing Notch4* AVMs-overexpression of arterial markers (Efnb2, Dll4, Jag1, and Cx40) is decreased, and venous marker expression (Ephb4) is restored ( Figure 3D ). The normalization of these high-flow AV shunts by a single genetic correction has conceptually changed our view on AVM treatment. The discovery that suppression of a causal gene can lead to AVM regression in mice, without hemorrhage or thrombosis, may change the way we think about AVM pathogenesis and treatment.
Concluding Remarks
Mouse models of human BAVM disease provide a useful platform for elucidating the mechanisms of AVM pathogenesis and for exploring treatment options. Moving forward, the identification of additional genetic perturbations associated with BAVM, through continued investigation of both mouse and human genetic studies, will open new opportunities for the rational design and development of better treatment options for this disease. 
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